🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07260799
Active, not recruiting Observational

Clinical Performance of Capillary Blood Samples Collected Using the Tasso+ Serum Gel Capillary Blood Collection System for Clinical Chemistry Testing of 14 Analytes on an Abbott Alinity Analyzer

NCT07260799 · tracked via the Priya Life Science USA tracker
Sponsor
Tasso Inc.
Phase
Observational
Started
2025-10-25
Last updated
2026-07-20

Condition(s) studied

Serum Analytes

Investigational drug(s) / intervention(s)

Tasso+ Serum Gel Capillary Blood Collection System

Tasso+ Serum Gel Capillary Blood Collection System: Clinical evaluation of capillary blood samples collected using the Tasso+ Serum Gel Capillary Blood Collection System for downstream analyte testing.

Study summary

The purpose of this single-visit study is to demonstrate the performance of capillary blood samples collected with the Tasso+ Serum Gel Capillary Blood Collection System compared to venous reference samples for downstream analyte testing at a clinical laboratory.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Adults aged 18-85 years with no previous experience with the Tasso+ lancet 2. Willing and able to provide written informed consent prior to study entry 3. Willing and able to adhere to study assessments, schedule, prohibitions and restrictions as described in the protocol 4. Healthy individuals or patients with abnormal analyte values (verified or likely to be) within intended clinical reference ranges as indicated by standard of care testing and/or past medical history, in the judgement of the investigator Exclusion Criteria: 1. Present with abnormal skin integrity or atypical skin health near/on arm collection sites 2. Mental or physical impairment which would preclude participation in the judgement of the investigator or qualified designee 3. Trained clinical laboratory and healthcare personnel who have worked in the field in the previous 5 years 4. Any condition which, in the opinion of the investigator or delegate, makes the participant unsuitable for this study (including, but not limited to, any mental or physical impairment which would preclude provision of adequate and knowledgeable consent)

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Celesta / American Research Labs Atlantis Florida
Tasso, Inc. Seattle Washington
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07260799 on ClinicalTrials.gov ↗ ← All trials in the USA